2-Hydroxyphytanoyl-CoA lyase (abbreviated as 2-HPCL), renamed to 2-hydroxyacyl-CoA lyase (abbreviated as HACL1), is the first peroxisomal enzyme in mammals that has been found to be dependent on TPP (thiamin pyrophosphate). It was discovered in 1999, when studying α-oxidation of phytanic acid. HACL1 has an important role in at least two pathways: (i) the degradation of 3-methyl-branched fatty acids like phytanic acid and (ii) the shortening of 2-hydroxy long-chain fatty acids. In both cases, HACL1 catalyses the cleavage step, which involves the splitting of a carbon-carbon bond between the first and second carbon atom in a 2-hydroxyacyl-CoA intermediate leading to the production of an (n − 1) aldehyde and formyl-CoA. The latter is rapidly converted into formate and subsequently to CO 2 . HACL1 is a homotetramer and has a PTS (peroxisomal targeting signal) at the C-terminal side (PTS1). No deficiency of HACL1 has been described yet in human, but thiamin deficiency might affect its activity.
Introduction
α-Oxidation is the process by which fatty acids are degraded by one carbon unit. It is the main degradation pathway for 3-methyl-branched fatty acids such as phytanic acid (3,7,11,15- tetramethylhexadecanoic acid) before these can enter the β-oxidation sequence as the 3-methyl substitution renders the third step of β-oxidation impossible. Elucidation of the exact phytanic acid α-oxidation sequence was greatly facilitated by the detection of formate as one of its products in 1993 [1] . The pathway consists of an initial activation, subsequent 2-hydroxylation by a dioxygenase, splitting of the 2-hydroxy-3-methylacyl-CoA intermediate into an (n − 1) aldehyde and formyl-CoA in the third step and subsequent dehydrogenation of the formed 2-methylbranched aldehyde [2] . Not only phytanic acid is degraded by this pathway, but also synthetic 3-methyl-branched fatty acids, as shown by our earlier study [3] .
The present paper mainly concerns the third step of this pathway and the responsible enzyme.
Croes et al. [4] identified the carbon unit that is split off from the 2-hydroxy-3-methylacyl-CoA intermediate in the
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third step as formyl-CoA. The release of formyl-CoA led to the hypothesis that the second end-product of α-oxidation would be a fatty aldehyde rather than a fatty acid [4] . Already back in 1969, Mize et al. [5] had suggested the potential formation of an aldehyde intermediate in the process of phytanic acid α-oxidation, but this idea was only substantiated in 1997 by the detection of the 2-methylbranched fatty aldehyde with one carbon less in incubations of rat liver peroxisomes [6] and human liver homogenate [7] . The formation of the (n − 1) aldehyde and formyl-CoA, which are produced in equimolar amounts, pointed towards an enzymatic reaction in which a carbon-carbon bond is cleaved. Foulon et al. [8] found that this enzymatic activity co-localized with catalase to the peroxisomal matrix in rat liver, in accordance with the earlier observed distribution of the whole α-oxidation process in rat liver [9] . Starting from the matrix protein fraction of isolated rat liver peroxisomes, Foulon et al. [8] purified, sequenced and characterized the responsible enzyme and called it 2-hydroxyphytanoylCoA lyase (abbreviated as 2-HPCL). It appeared to be a homotetrameric enzyme with subunits of 63 kDa, and the C-terminal sequence SNM (of the human lyase), preceded by a positive charge (in this case RSNM), was found to be a hitherto unknown PTS1 (peroxisomal targeting signal 1) signal [8] .
The lyase had initially been purified in the absence of TPP (thiamin pyrophosphate) and the enzyme lost virtually all of its activity during purification. The amino acid sequences of tryptic peptides from the purified and barely active lyase suggested that the cleavage enzyme is related to a putative Caenorhabditis elegans protein that displays homology to bacterial oxalyl-CoA decarboxylases [10, 11] . These enzymes, which have only been described in bacteria, catalyse the TPP-dependent decarboxylation of oxalyl-CoA to formyl-CoA and CO 2 [10, 11] and contain, like all known TPP-dependent enzymes, a TPP-binding consensus motif, defined as G-D-G-X 24−27 -N-N [12] . The homology between these decarboxylases and 2-HPCL suggested that the lyase also requires TPP. Activity of 2-HPCL could indeed be restored or preserved when TPP was added and optimum activity for the purified enzyme was reached at 20 µM TPP in the presence of 0.8 mM Mg 2+ [8] . In addition, the TPP-binding consensus domain could be identified in the C-terminal part of the lyase. The peptide sequences of this domain in the rat, mouse and human enzyme comply exactly with the TPP-binding consensus domain of pyruvate decarboxylase of Saccharomyces cerevisiae, acetolactate synthase of Escherichia coli, oxalyl-CoA decarboxylase of Oxalobacter formigenes and the putative oxalyl-CoA decarboxylases of C. elegans and S. cerevisiae [13] .
In contrast with a purely peroxisomal localization in rat liver [8] , the subcellular distribution of 2-HPCL activity in human liver shows a bimodal distribution between peroxisomes and endoplasmic reticulum [13] . This microsomal activity could be an explanation for a normal lyase activity found in liver of patients with Zellweger syndrome [13, 14] . However, in order to explain the latter finding, Jansen et al. [14] referred to other peroxisomal enzymes, like catalase, that retain their activity when non-imported into the peroxisome and made no reference to a potential microsomal localization.
A role for HACL1 (2-hydroxyacyl-CoA lyase 1) in the degradation of 2-hydroxy fatty acids
As the first identified substrate for the lyase contains a 3-methyl branch, a 2-hydroxy group and a CoA moiety, the next question concerned the substrate specificity: which of these constituents are mandatory for a compound in order to be a substrate for the lyase? Substrate competition experiments with long-chain 2-hydroxyacyl-CoAs, 2-hydroxy-3-methylacyl-CoA, 3-methylacyl-CoA, and long-chain fatty acids containing a 2-or 3-methyl branch or a 2-or 3-hydroxy group led to the conclusion that both the 2-hydroxy moiety and the CoA-ester function, but not the 3-methyl substitution, are obligatory in order to be a substrate for this enzyme [15] . These findings suggested that 2-HPCL also plays a role in the degradation of 2-hydroxy very long straight-chain fatty acids, which are abundantly present in sphingolipids of brain myelin, namely cerebrosides and sulfatides [16] .
It had already been postulated that 2-hydroxy straightchain fatty acids of brain sphingolipids can undergo α-oxidation. These fatty acids would be derived from the corresponding non-hydroxy fatty acids and then degraded to odd-numbered fatty acids with one carbon atom less [17] [18] [19] . However, α-hydroxylation of straight-chain fatty acids and degradation of 2-hydroxy fatty acids are no sequential processes, distinguishing this process from the α-oxidation of 3-methyl-branched fatty acids in liver. Indeed, brain α-hydroxylation is an anabolic process as the formed 2-hydroxy fatty acid is incorporated into the lipids of the brain, whereas α-hydroxylation (of phytanic acid) in liver is part of a catabolic process.
Experiments with 2-hydroxyoctadecanoyl-CoA showed that this fatty acyl-CoA is degraded in peroxisomes to formyl-CoA/formate and an (n − 1) aldehyde, heptadecanal, in a TPP-dependent manner, indicating that α-oxidation of 2-hydroxyacyl-CoAs resembles that of 2-hydroxy-3-methylacyl-CoAs [15] . Incubations of 2-hydroxyoctadecanoyl-CoA with the recombinant human 2-HPCL enzyme finally proved that, besides 2-hydroxy-3-methylacyl-CoA, also 2-hydroxy long-chain fatty acyl-CoAs are substrates for the lyase [15] . Most likely, 2-hydroxy very-long-chain fatty acids are degraded in a similar manner. Consequently, it was proposed to refer to this enzyme as 2-hydroxyacyl-CoA lyase, abbreviated as HACL1 (in conformity with the recommended gene symbol HACL1; http://www.gene.ucl.ac.uk/ nomenclature/data/get_data.php?hgnc_id=17856), which stresses its broader role in the degradation of 2-hydroxy fatty acids, with or without a 3-methyl substitution.
The amount of 2-hydroxy fatty acids rapidly increases during myelination, indicating that myelination and 2-hydroxylation of fatty acids are closely linked [21] . Moreover, 2-hydroxylation is believed to be the rate-limiting step in the synthesis of cerebrosides [22] .
Identification of HACL1 as the enzyme catalysing the degradation of 2-hydroxy fatty acids may then be of importance regarding the maintenance of myelin.
Thiamin dependence of HACL1
Thiamin (vitamin B 1 ) is a water-soluble micronutrient essential for normal cellular functions, growth and development of humans and other higher eukaryotes, which cannot synthesize thiamin but depend on an appropriate dietary intake and absorption of this vitamin. Upon entry into cells, thiamin is quickly converted into its biologically active form, TPP, by TPK (thiamin pyrophosphokinase). TPP functions as a prosthetic group for the mitochondrial enzymes pyruvate dehydrogenase, α-oxoglutarate dehydrogenase and branched-chain α-keto acid dehydrogenase. In addition, TPP is involved in the cytosolic pentose-phosphate pathway as coenzyme for transketolase. After discovering a role for TPP in the cleavage step of α-oxidation, we could point to HACL1 as the first example of a TPP-dependent enzyme in mammalian peroxisomes. The fact that HACL1 has a role in lipid metabolism and uses a 2-hydroxy carboxyl and not a 2-keto carboxyl moiety as substrate, distinguishes it from the previously described TPP-dependent enzymes.
All known TPP-dependent enzymes are di-or tetra-meric complexes with subunits of approx. 63 kDa. It has been Reaction of a TPP-dependent enzyme with its substrate involves the formation of a carbanion. A key function herein is the interaction of a conserved glutamate residue with the N1 atom of the coenzyme, resulting in an increased basicity of its 4 amino group, which facilitates the deprotonation of the C2 [25, 26] .
shown that TPP binds across the interface of two subunits [23] , indicating a role for TPP in creating subunit interactions. At least for some (tetrameric) TPP-dependent enzymes, the dimeric form appears to be the minimal functional unit [23] . This has not yet been shown for HACL1, but it remains possible that both the dimeric and the tetrameric form have enzymatic activity.
In all TPP-dependent reactions described so far, catalysis involves activation of the C2-H of the thiazole ring, followed by a nucleophilic attack at the carbonyl carbon of the substrate [24, 25] . Kern et al. [25] reported that in the enzymebound state, the C2 atom of TPP is protonated, as in free TPP, but that the enzyme highly accelerates the deprotonation, producing a reactive C2 carbanion intermediate. It seems plausible that the formation of a carbanion is also required for the cleavage of 2-hydroxyacyl-CoAs by HACL1 [2] . This carbanion would then likely attack carbon 1 of the substrate, which is highly reactive due to the presence of the thioester bond, leading to the formation of formyl-CoA and an (n − 1) aldehyde ( Figure 1 ) [2] .
How does TPP/thiamin get into the mammalian peroxisome?
Two important questions arose when HACL1 was established as a peroxisomal and TPP-dependent enzyme: (i) Does TPP enter the peroxisome as TPP or as thiamin? (ii) How does TPP/thiamin enter the peroxisome, where it is needed as a cofactor? Studies on the intraperoxisomal thiamin/TPP contents had never been carried out and no data were available about a potential import of these cofactors.
In order to address the first question, the presence of thiamin and TPP was studied in subcellular rat liver fractions and organelles separated by density-gradient centrifugation. It appeared [27] that in purified peroxisomes thiamin is predominantly present in the form of TPP. An intraperoxisomal conversion of thiamin into TPP is very unlikely as the necessary enzyme for this conversion, TPK, is exclusively located in the cytosolic fraction [27, 28] , has no PTS and is absent from purified peroxisomes [27] . These observations lead us to conclude that TPP, and not thiamin, is transported into the peroxisome [27] .
With regard to the second question, much more uncertainty remains. At present, nothing is known about the transport of thiamin or its phosphate esters across the peroxisomal membrane. Several possibilities can be envisaged: through (aspecific) pores in the peroxisomal membrane, by specific TPP transporters in the peroxisomal membrane or through import in association with HACL1.
Concerning permeability for cofactors, the peroxisomal single membrane has some peculiar characteristics, as passage of small water-soluble molecules is possible according to some authors [29, 30] .
Concerning peroxisomal import of TPP by specific transporters, nothing is known yet. Solute thiamin transporters [SLC19A (solute carrier family 19) gene family] have been described in the mitochondrial and cellular membrane [31] [32] [33] [34] , but transport of phosphorylated thiamin by thiamin transporters ThTr1 (SLC19A2) and ThTr2 (SCL19A3) has not been described. However, transport of TPP and TMP (thiamin monophosphate) over the cell membrane can occur via RFC1 (reduced folate transporter 1; SLC19A1) [35] , and also transport of TPP over the mitochondrial membrane has been reported [36] . In addition, several putative mitochondrial solute carriers (SLC25A family) are present in the human genome and it cannot be excluded that one of these is a peroxisomal TPP transporter. In this context, it should be mentioned that the mitochondrial SLC25A19 transporter, thought to be involved in deoxyribonucleotide transport, can transport TPP [33] . For peroxisomes, only one solute transporter, which functions as ADP/ATP exchange carrier in yeast [37] , has been functionally cloned. The human orthologue, SLC25A17 (PMP34), also recognizes ATP [38] . Transport of phosphate and possibly PP i has been described in proteoliposomes containing peroxisomal membrane proteins of bovine kidney [39] , but the putative transporter has not yet been identified.
Finally, import of TPP in association with HACL1 is a possibility. HACL1 is imported from the cytosol into peroxisomes by means of Pex5p, the PTS1 import receptor [8] . As peroxisomal matrix proteins do not need to be unfolded during the import process, the possibility that TPP is imported in the peroxisomal matrix bound to HACL1 needs to be explored. Such an import mechanism of a protein, in association with a cofactor, has been suggested for rat catalase [40] . In Hansenula polymorpha, a peroxisomal TPP-dependent DHAS (dihydroxyacetone synthase) was demonstrated to enter the peroxisome in an enzymatically active dimeric form, but no conclusive evidence was provided about the binding of TPP during import [41] .
Impact of thiamin deficiency?
The identification of the TPP-dependent HACL1, involved in the α-oxidation of phytanic acid and of 2-hydroxy straight-chain fatty acids, pointed towards a role of vitamin B in these processes. Consequently, the effect of TPP/thiamin deficiency on HACL1 and α-oxidation was studied in several thiamin-deficient models: (i) in cells cultured under low thiamin conditions, obtained by adding oxythiamin to the medium or by growing cells in thiamin-depleted medium; (ii) in rats fed a thiamin-deficient diet; and (iii) in fibroblasts of patients with TRMA (thiamin-responsive megaloblastic anaemia) [42] . The results pointed to a clear thiamin dependence of total α-oxidation. Furthermore, the importance of TPP/thiamin in the α-oxidation pathway was stressed by the deleterious effects seen in rats given a thiamin-deficient diet enriched in phytol, the precursor of phytanic acid, which is, under normal conditions, α-oxidized to pristanic acid and further β-oxidized in peroxisomes [42] .
Given the decreased HACL1 activity and affected α-oxidation under thiamin-depleted conditions [42] , it can be expected that under clinical conditions when dietary thiamin is restricted (beriberi, Wernicke-Korsakoff syndrome [43] ), α-oxidation is impaired. It is at present unclear how deficient degradation of both substrates of HACL1, phytanic acid and 2-hydroxy straight-chain fatty acids, can be linked to the symptoms seen in thiamin-deficient states. Likely, the slower degradation of 2-hydroxy straight-chain fatty acids, originating from the turnover of sphingolipids, will have a higher impact than the reduced phytanic acid breakdown.
Impact of HACL1 deficiency?
The human HACL1 gene has been mapped to chromosome 3p25 (V. Foulon, J. Vermeesch, M. Casteels and P.P. Van Veldhoven, unpublished work), a locus confirmed later by the human genome sequencing project. The complete gene spans 40.8 kb and contains 17 exons, with intron sizes ranging from 190 to 4700 bp and all exon-intron boundaries conform to the consensus rules [44] , ending in an AG doublet and starting with a GT pair. No diseases have been linked to this gene locus yet and an HACL1 deficiency has never been described in human, as a result of which the phenotype is unknown [2] . One can presume that, apart from an accumulation of 2-hydroxyphytanic acid (or its CoA-ester), also phytanic acid will increase (in adult Refsum's disease, this leads to neurological symptoms, most often after several decades [45] ). In addition, 2-hydroxy fatty acids (or their CoA-esters) may increase, with potentially more serious neurological symptoms of earlier onset. Furthermore, it is likely that HACL1 plays a role in other processes in which 3-methyl-branched fatty acids or precursors (e.g. degradation of prenoid aldehydes, which are formed in lysosomes during the decomposition of prenylated proteins [46] ) or 2-hydroxy fatty acids are formed as intermediates (e.g. α-oxidation of very-long-chain fatty acids in brain).
